Cepton, Inc.: Nasdaq/NYSE listing notice — Cepton receives Nasdaq bid price deficiency notice; 180-day cure period until Oct 10, 2023

Cepton, Inc.

Nasdaq notified Cepton on April 13, 2023, that its common stock failed to maintain $1.00 minimum bid for 30 consecutive business days.
Company has until October 10, 2023 to regain compliance by closing at $1.00+ for 10 consecutive business days.
If not cured, Cepton may qualify for an additional 180-day period if it meets other listing requirements and plans a reverse stock split.
Failure to cure could lead to delisting from The Nasdaq Capital Market; Cepton may appeal any delisting determination.
Cepton is considering options to regain compliance; stock continues trading under CPTN on Nasdaq.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Cepton, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

April 13, 2023, Cepton, Inc. (the “ Company ”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that, for the 30 consecutive business day period beginning March 1, 2023 and ending April 12, 2023, the Company was not in compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”). The Notice does not result in the immediate delisting of the Company’s common stock from The Nasdaq Capital Market

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001498233-23-000024

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.